DDrare: Database of Drug Development for Rare Diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
299	嚢胞性線維症	1

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01695343 (ClinicalTrials.gov)	December 2012	25/9/2012	Study to Evaluate the Effect of KB001-A on Time-to-Need for Antibiotic Treatment	A Phase 2, Randomized, Double-blind, Placebo-controlled, Repeat-dose Study of KB001-A in Subjects With Cystic Fibrosis Infected With Pseudomonas Aeruginosa	Cystic Fibrosis	Biological: KB001-A;Drug: Placebo Comparator	KaloBios Pharmaceuticals	NULL	Completed	12 Years	50 Years	Both	182	Phase 2	United States;Australia;Israel;New Zealand

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT01695343
(ClinicalTrials.gov)

December 2012

25/9/2012

Study to Evaluate the Effect of KB001-A on Time-to-Need for Antibiotic Treatment

A Phase 2, Randomized, Double-blind, Placebo-controlled, Repeat-dose Study of KB001-A in Subjects With Cystic Fibrosis Infected With Pseudomonas Aeruginosa

Cystic Fibrosis

Biological: KB001-A;Drug: Placebo Comparator

KaloBios Pharmaceuticals

NULL

Completed

12 Years

50 Years

Both

182

Phase 2

United States;Australia;Israel;New Zealand